Siemens Healthineers AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Bernhard Montag
- Full Time Employees
- 74,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Siemensstr. 3 Forchheim BV Germany 91301
- IPO Date
- Aug 4, 2023
- Website
- siemens-healthineers.com
- Similar Companies
- Business
- Siemens Healthineers AG develops, manufactures and markets diagnostic and therapeutic products and services worldwide. The company provides imaging systems including computed tomography scanners, magnetic resonance imaging equipment, angiography and X-ray systems, ultrasound devices and molecular imaging solutions; laboratory diagnostics encompassing in-vitro testing, point-of-care diagnostics and informatics platforms; advanced therapies such as image-guided systems for interventional procedures, angiography platforms including robotic-assisted tools and mobile C-arms; radiation oncology equipment through its Varian segment covering linear accelerators and treatment planning software; and AI-enabled digital health solutions like AI-Rad Companion and AI-Pathway Companion for oncology and precision medicine. Siemens Healthineers AG operates globally with major facilities in Europe, North America and Asia, serving hospitals, clinics and laboratories in areas including oncology, cardiology, neurology and infectious diseases. Founded in 2016 as a rebranding of Siemens Healthcare and headquartered in Erlangen, Germany, the company employs around 65,000 people. In November 2025, Siemens Healthineers AG announces a new strategy phase "Elevating Health Globally" with restructured segments focused on Imaging for prevention and detection, Precision Therapy combining Varian, Advanced Therapies and Ultrasound for treatment, and standalone Diagnostics; mid-term financial targets emphasize AI-driven efficiencies targeting stroke, cancer, cardiovascular and neurodegenerative diseases. Siemens AG plans to deconsolidate its remaining approximately 67% stake in Siemens Healthineers, following prior divestitures including a 2% stake sale in February 2025 raising €1.45 billion, as part of portfolio simplification toward pure-play technology. Recent expansions include a $32 million manufacturing facility in Newark, Delaware for in-vitro diagnostics and AI applications; acquisition in December 2024 of Advanced Accelerator Applications Molecular Imaging from Novartis for over $224 million, adding radioligand production and 420 employees; €25 million investment in Rudolstadt, Germany site for CT and angiography components creating 50 jobs by 2027; and opening of new Erlangen headquarters in 2024. In September 2025, Siemens deepens life sciences partnership with Merck KGaA via MoU leveraging Dotmatics acquisition for AI drug discovery workflows.
Company News
Siemens Healthineers: Successful Investment, Updating For H2 2026
Siemens Healthineers Cuts Revenue Outlook on Diagnostics Weakness
Siemens Healthineers cuts revenue forecast citing diagnostics weakness
AiM Medical Robotics Announces Collaboration Agreement with Siemens Healthineers to Advance MRI-Guided Robotic Neurosurgery
Siemens Healthineers: Update Post The Carve-Out Announcement
Siemens Healthineers (OTCMKTS:SEMHF) Shares Down 1.2% – Here’s What Happened
Siemens Healthineers AG (SEMHF) Q3 2025 Earnings Call Transcript
Siemens Healthineers AG (SEMHF) Q2 2025 Earnings Call Transcript
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
Siemens Healthineers AG (SEMHF) Q1 2025 Earnings Call Transcript
Siemens Healthineers AG (SEMHF) Q4 2024 Earnings Call Transcript